Patents by Inventor ROSS A. STEWARD

ROSS A. STEWARD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS
    Publication number: 20220204527
    Abstract: The specification relates to compounds of Formula (A) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: March 3, 2020
    Publication date: June 30, 2022
    Inventors: Jason Grant KETTLE, Iain SIMPSON, Christopher PHILLIPS, Scott BOYD, Oliver Ross STEWARD, Michael Steven BODNARCHUK, Doyle Joseph CASSAR, Kurt Gordon PIKE
  • Autotaxin inhibitors
    Patent number: 10183025
    Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: January 22, 2019
    Assignee: Novartis AG
    Inventors: David Beattie, Urs Baettig, Darren Mark Le Grand, Andrew Stuart Lister, Jeffrey McKenna, David William Pearce, David Andrew Sandham, Oliver Ross Steward, Christopher Thomson
  • AUTOTAXIN INHIBITORS
    Publication number: 20180021345
    Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
    Type: Application
    Filed: August 9, 2017
    Publication date: January 25, 2018
    Applicant: Novartis AG
    Inventors: David BEATTIE, Urs BAETTIG, Darren Mark LE GRAND, Andrew Stuart LISTER, Jeffrey MCKENNA, David William PEARCE, David Andrew SANDHAM, Oliver Ross STEWARD, Christopher THOMSON
  • Autotaxin inhibitors
    Patent number: 9763957
    Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: September 19, 2017
    Assignee: Novartis AG
    Inventors: David Beattie, Urs Baettig, Darren Mark Legrand, Andrew Stuart Lister, Jeffrey McKenna, David William Pearce, David Andrew Sandham, Oliver Ross Steward, Christopher Thomson
  • TARGETED BINDING AGENTS AGAINST B7-H1
    Publication number: 20170137522
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Application
    Filed: October 25, 2016
    Publication date: May 18, 2017
    Applicant: MEDIMMUNE LIMITED
    Inventors: CHRISTOPHE QUEVA, MICHELLE MORROW, SCOTT HAMMOND, MARAT ALIMZHANOV, JOHN BABCOCK, IAN Nevin FOLTZ, JASPAL SINGH KANG, LAURA SEKIROV, MELANIE BOYLE, MATTHIEU CHODORGE, ROSS A. STEWARD, KATHLEEN ANN MULGREW
  • Targeted binding agents against B7-H1
    Patent number: 9493565
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: November 15, 2016
    Assignee: MedImmune Limited
    Inventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcock, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Steward, Kathleen Ann Mulgrew
  • AUTOTAXIN INHIBITORS
    Publication number: 20160184318
    Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
    Type: Application
    Filed: July 16, 2014
    Publication date: June 30, 2016
    Applicant: Novartis AG
    Inventors: David BEATTIE, Urs BAETTIG, Darren Mark LEGRAND, Andrew Stuart LISTER, Jeffrey MCKENNA, David William PEARCE, Ddavid Andrew SANDHAM, Oliver Ross STEWARD, Christopher Thomson
  • AUTOTAXIN INHIBITORS
    Publication number: 20160168119
    Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
    Type: Application
    Filed: July 16, 2014
    Publication date: June 16, 2016
    Applicant: Novartis AG
    Inventors: Urs BAETTIG, David BEATTIE, Darren Mark LEGRAND, Andrew Stuart LISTER, Jeffrey MCKENNA, David William PEARCE, David Andrew SANDHAM, Emily STANLEY, Oliver Ross STEWARD, Christopher THOMSON
  • TARGETED BINDING AGENTS AGAINST B7-H1
    Publication number: 20140356353
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Application
    Filed: May 6, 2014
    Publication date: December 4, 2014
    Inventors: CHRISTOPHE QUEVA, MICHELLE MORROW, SCOTT HAMMOND, MARAT ALIMZHANOV, JOHN BABCOCK, IAN Nevin FOLTZ, JASPAL SINGH KANG, LAURA SEKIROV, MELANIE BOYLE, MATTHIEU CHODORGE, ROSS A. STEWARD, KATHLEEN ANN MULGREW